Research Analysts Issue Forecasts for ACTU Q1 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Actuate Therapeutics in a report issued on Monday, August 18th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.25) for the quarter. HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.27) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at ($0.99) EPS and FY2029 earnings at $0.21 EPS.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its quarterly earnings data on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.11).

Separately, Wall Street Zen cut Actuate Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $20.50.

Actuate Therapeutics Stock Performance

NASDAQ:ACTU traded up $0.70 during trading hours on Tuesday, reaching $8.36. The company had a trading volume of 58,818 shares, compared to its average volume of 64,528. The stock has a 50-day moving average of $7.05 and a two-hundred day moving average of $7.93. Actuate Therapeutics has a one year low of $5.47 and a one year high of $11.99.

Hedge Funds Weigh In On Actuate Therapeutics

Large investors have recently modified their holdings of the stock. Chicago Partners Investment Group LLC bought a new stake in shares of Actuate Therapeutics during the first quarter valued at approximately $70,000. Sfmg LLC bought a new position in Actuate Therapeutics in the 1st quarter worth approximately $74,000. Envestnet Asset Management Inc. acquired a new position in Actuate Therapeutics during the 4th quarter worth $83,000. OMERS ADMINISTRATION Corp acquired a new position in Actuate Therapeutics during the 4th quarter worth $84,000. Finally, Bank of America Corp DE boosted its position in Actuate Therapeutics by 61,068.0% in the 2nd quarter. Bank of America Corp DE now owns 15,292 shares of the company's stock valued at $93,000 after buying an additional 15,267 shares during the last quarter.

Insider Activity

In other news, Director Equity Cof Lp Bios bought 71,428 shares of the business's stock in a transaction dated Friday, June 27th. The stock was bought at an average price of $7.00 per share, for a total transaction of $499,996.00. Following the completion of the purchase, the director owned 196,428 shares of the company's stock, valued at approximately $1,374,996. The trade was a 57.14% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Aaron G.L. Fletcher acquired 71,428 shares of the firm's stock in a transaction on Friday, June 27th. The shares were bought at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the acquisition, the director owned 196,428 shares in the company, valued at approximately $1,374,996. The trade was a 57.14% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 214,284 shares of company stock worth $1,499,988. Insiders own 69.34% of the company's stock.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.